Trial of lixisenatide in early Parkinson's disease

WG Meissner, P Remy, C Giordana… - … England Journal of …, 2024 - Mass Medical Soc
Background Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment
of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease …
被引用次数：41 相关文章

Trial of Lixisenatide in Early Parkinson's Disease

WG Meissner, P Remy, C Giordana… - The New England …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment
of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease …

Trial of Lixisenatide in Early Parkinson's Disease.

WG Meissner, P Remy, C Giordana… - The New England …, 2024 - europepmc.org
Background Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment
of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease …

Trial of Lixisenatide in Early Parkinson's Disease

W Meissner, P Remy, C Giordana… - … England Journal of …, 2024 - u-picardie.hal.science
Background: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment
of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease …

[引用][C] Trial of Lixisenatide in Early Parkinson's Disease.

WG Meissner, P Remy, C Giordana, D Maltête… - 2024 - lilloa.univ-lille.fr
Trial of Lixisenatide in Early Parkinson's Disease. Toggle navigation English français Aide | Contact
| À Propos | Ouvrir une session Portail HAL | Pages Pro Chercheurs EN / FR Toggle navigation Voir …